Lilly invests $2.5B in new German site to boost tirzepatide supply, $100M for local biotechs

Eli Lil­ly is set to build a new $2.5 bil­lion fa­cil­i­ty in Ger­many to in­crease man­u­fac­tur­ing ca­pac­i­ty for its block­buster di­a­betes and obe­si­ty drugs, and the phar­ma gi­ant al­so an­nounced Fri­day it will spend up to $100 mil­lion on lo­cal biotechs.

The fa­cil­i­ty will be lo­cat­ed in Alzey, which is about an hour dri­ve from Frank­furt. It’s ex­pect­ed to boost the com­pa­ny’s in­jectable pro­duc­tion as well as its de­vice man­u­fac­tur­ing ca­pa­bil­i­ties and, ul­ti­mate­ly, in­crease Lil­ly’s in­cretin sup­ply. Lil­ly’s block­buster drug tirzepatide — ap­proved as Moun­jaro for type 2 di­a­betes and Zep­bound for obe­si­ty — tar­gets GIP and GLP-1 re­cep­tors, which are nat­u­ral­ly ac­ti­vat­ed by in­cretin hor­mones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.